Corbus Pharmaceuticals Q3 net loss widens on higher expenses
CRBP•Corbus Pharmaceuticals reported a third-quarter net loss of $37.75 million, or $1.81 per basic share, and operating expenses of $38.82 million. The company said cash on hand is expected to fund operations into 2028.
1. Quarterly results
Corbus Pharmaceuticals reported a third-quarter net loss of $37.75 million and a loss of $1.81 per basic share. Operating expenses were $38.82 million, rising year over year mainly because of higher research and development costs and a $15 million milestone payment under its CSPC agreement for sutantatug envedotin.
2. Clinical programs
The company began dosing patients in its registrational TEMPO-1 study for oropharyngeal cancer and reported positive topline Phase 1b data for CRB-913 in obesity. Corbus plans to engage with the FDA on CRB-913 development and a possible combination with GLP-1 therapy.
3. Cash and outlook
Corbus expects its cash on hand to fund operations into 2028. It expects to report data on sutantatug envedotin plus Keytruda in first-line oropharyngeal cancer in the first quarter of 2027.
